Study 5 of 40 for search of: "Parotitis"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This study has been completed.
Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00127023
  Purpose

This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.


Condition Intervention Phase
Measles
Mumps
Rubella
Chickenpox
Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
Phase III

MedlinePlus related topics: Chickenpox Measles Mumps Rubella Shingles
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Parallel Assignment, Safety Study
Official Title: Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Antibody levels after vaccination.

Secondary Outcome Measures:
  • Safety of the study vaccines.

Estimated Enrollment: 944
Study Start Date: May 2005
Detailed Description:

Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.

  Eligibility

Ages Eligible for Study:   11 Months to 21 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.

Exclusion Criteria:

  • History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
  • Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00127023

  Hide Study Locations
Locations
Germany
GSK Investigational Site
Berlin, Germany, 13055
GSK Investigational Site
Berlin, Germany, 12627
GSK Investigational Site
Berlin, Germany, 14197
GSK Investigational Site
Berlin, Germany, 10999
GSK Investigational Site
Hamburg, Germany, 22307
GSK Investigational Site
Berlin, Germany, 12679
GSK Investigational Site
Hamburg, Germany, 22143
GSK Investigational Site
Hamburg, Germany, 22089
GSK Investigational Site
Berlin, Germany, 10967
Germany, Baden-Wuerttemberg
GSK Investigational Site
Bretten, Baden-Wuerttemberg, Germany, 75015
GSK Investigational Site
Tauberbischofsheim, Baden-Wuerttemberg, Germany, 97941
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68161
GSK Investigational Site
Offenburg, Baden-Wuerttemberg, Germany, 77656
GSK Investigational Site
Oberstenfeld, Baden-Wuerttemberg, Germany, 71720
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70469
GSK Investigational Site
Kirchzarten, Baden-Wuerttemberg, Germany, 79199
GSK Investigational Site
Ettenheim, Baden-Wuerttemberg, Germany, 77955
GSK Investigational Site
Offenburg, Baden-Wuerttemberg, Germany, 77654
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68309
GSK Investigational Site
Ludwigsburg, Baden-Wuerttemberg, Germany, 71634
GSK Investigational Site
Tettnang, Baden-Wuerttemberg, Germany, 88069
GSK Investigational Site
Boennigheim, Baden-Wuerttemberg, Germany, 74357
GSK Investigational Site
Eppelheim, Baden-Wuerttemberg, Germany, 69214
GSK Investigational Site
Schwaebisch-Hall, Baden-Wuerttemberg, Germany, 74523
GSK Investigational Site
Oberkirch, Baden-Wuerttemberg, Germany, 77704
GSK Investigational Site
Bad Saulgau, Baden-Wuerttemberg, Germany, 88348
GSK Investigational Site
Marbach, Baden-Wuerttemberg, Germany, 71672
GSK Investigational Site
Ehingen, Baden-Wuerttemberg, Germany, 89584
Germany, Bayern
GSK Investigational Site
Marktheidenfeld, Bayern, Germany, 97828
GSK Investigational Site
Bindlach, Bayern, Germany, 95463
GSK Investigational Site
Muenchen, Bayern, Germany, 81241
GSK Investigational Site
Nuernberg, Bayern, Germany, 90473
GSK Investigational Site
Augsburg, Bayern, Germany, 86163
GSK Investigational Site
Roding, Bayern, Germany, 93426
Germany, Hessen
GSK Investigational Site
Fulda, Hessen, Germany, 36037
Germany, Mecklenburg-Vorpommern
GSK Investigational Site
Waren, Mecklenburg-Vorpommern, Germany, 17192
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18146
GSK Investigational Site
Buetzow, Mecklenburg-Vorpommern, Germany, 18246
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18059
Germany, Niedersachsen
GSK Investigational Site
Salzgitter, Niedersachsen, Germany, 38226
GSK Investigational Site
Wolfenbuettel, Niedersachsen, Germany, 38302
Germany, Nordrhein-Westfalen
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44866
GSK Investigational Site
Krefeld, Nordrhein-Westfalen, Germany, 47798
GSK Investigational Site
Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32549
GSK Investigational Site
Erkrath, Nordrhein-Westfalen, Germany, 40699
GSK Investigational Site
Willich, Nordrhein-Westfalen, Germany, 47877
GSK Investigational Site
Detmold, Nordrhein-Westfalen, Germany, 32756
GSK Investigational Site
Oberhausen, Nordrhein-Westfalen, Germany, 46145
GSK Investigational Site
Heiligenhaus, Nordrhein-Westfalen, Germany, 42579
GSK Investigational Site
Kleve-Materborn, Nordrhein-Westfalen, Germany, 47533
Germany, Rheinland-Pfalz
GSK Investigational Site
Bad Kreuznach, Rheinland-Pfalz, Germany, 55543
GSK Investigational Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67059
GSK Investigational Site
Frankenthal, Rheinland-Pfalz, Germany, 67227
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54290
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54294
GSK Investigational Site
Gerolstein, Rheinland-Pfalz, Germany, 54568
GSK Investigational Site
Worms, Rheinland-Pfalz, Germany, 67547
GSK Investigational Site
Bodenheim, Rheinland-Pfalz, Germany, 55294
Germany, Sachsen
GSK Investigational Site
Leipzig, Sachsen, Germany, 04178
GSK Investigational Site
Doebeln, Sachsen, Germany, 04720
GSK Investigational Site
Stollberg, Sachsen, Germany, 09366
GSK Investigational Site
Bischofswerda, Sachsen, Germany, 01877
GSK Investigational Site
Leipzig, Sachsen, Germany, 04317
Germany, Schleswig-Holstein
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24944
GSK Investigational Site
Neumuenster, Schleswig-Holstein, Germany, 24534
GSK Investigational Site
Moelln, Schleswig-Holstein, Germany, 23879
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24937
GSK Investigational Site
Bredstedt, Schleswig-Holstein, Germany, 25821
GSK Investigational Site
Niebuell, Schleswig-Holstein, Germany, 25899
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24943
GSK Investigational Site
Harrislee, Schleswig-Holstein, Germany, 24955
Germany, Thueringen
GSK Investigational Site
Lobenstein, Thueringen, Germany, 07356
GSK Investigational Site
Neuhaus am Rennweg, Thueringen, Germany, 98724
GSK Investigational Site
Weimar, Thueringen, Germany, 99425
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GSK ( Study Director )
Study ID Numbers: 104389
Study First Received: August 4, 2005
Last Updated: October 9, 2008
ClinicalTrials.gov Identifier: NCT00127023  
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by GlaxoSmithKline:
Prophylaxis measles, mumps, rubella and chickenpox

Study placed in the following topic categories:
Herpes Zoster
Mouth Diseases
Paramyxoviridae Infections
Measles
Chickenpox
Healthy
Rubella
Togaviridae Infections
Herpesviridae Infections
Virus Diseases
DNA Virus Infections
Chicken pox
Stomatognathic Diseases
Salivary Gland Diseases
Mumps

Additional relevant MeSH terms:
Rubivirus Infections
Parotid Diseases
RNA Virus Infections
Morbillivirus Infections
Parotitis
Rubulavirus Infections
Mononegavirales Infections

ClinicalTrials.gov processed this record on January 16, 2009